Rapid: a patient-centric, investigator-initiated, bayesian-designed, open-label, phase 2 platform trial of promising drugs for AYA patients with relapsed/refractory ewing sarcoma & dsrct
Active Grant Awarded
- Award ID
- R01FD008794
- Recipient
-
The Univeristy Of Texas M.d. Anderson Cancer Center UEI S3GMKS8ELA16
- Awarding agency
-
FDA Office of Acquisition and Grant Services
Food and Drug Administration, Department of Health and Human Services
- Obligated
- $899,917
Award facts
- Assistance listing
- 93.103 Food and Drug Administration Research
- Completion date 4% complete
- Funding agency
- Office of Medical Products and Tobacco Food and Drug Administration, Department of Health and Human Services
- Place of performance
- Houston, TX 77030, USA
Award details come from USAspending.gov.
About this award
The Department of Health and Human Services Food and Drug Administration awarded The University of Texas M.D. Anderson Cancer Center, doing business as MD Anderson Cancer Center, $899,917 on September 23, 2026, under Assistance Listing 93.103, Food and Drug Administration Research. The agency's structured record lists the alternate name Office of Medical Products and Tobacco. The award funds a RAPID trial, described as a patient-centric, investigator-initiated, Bayesian-designed, open-label, Phase 2 platform trial of promising drugs for AYA patients with relapsed or refractory Ewing sarcoma and desmoplastic small round cell sarcoma (DSRCT). Performance is located in Houston, Texas 77030. The period of performance runs from the September 23, 2026 award date to an ultimate completion date of June 30, 2030. Total funding and obligated amount are both $899,917.
Description
- Abstract
- & abstract drug development for ultra-rare cancers presents unique challenges, including slower trial accrual, reduced statistical power to detect a drug's safety and effectiveness, reduced sample access for modern-day tumor molecular profiling, and limited financial incentives for biotech and pharma to explore their drugs in ultra-rare cancers where the potential to recoup costs from R & D and funded trials is unlikely. Tumor biology presents its own challenges. For metastatic ewing sarcoma (ES), which affects ~150 people in the U.S. Each year, and desmoplastic small round cell sarcoma (DSRCT) that affects
Quick answers
Who received award R01FD008794?
R01FD008794 was awarded to The Univeristy Of Texas M.d. Anderson Cancer Center by FDA Office of Acquisition and Grant Services (Food and Drug Administration) on September 23, 2026.
How much is award R01FD008794 worth?
$899,917 has been obligated on R01FD008794.
Which agency awarded R01FD008794?
FDA Office of Acquisition and Grant Services (Food and Drug Administration) awarded R01FD008794, with funding from Office of Medical Products and Tobacco (Food and Drug Administration).
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award